Journal article Open Access
Guglielmetti, Caroline; Le Blon, Debbie; Santermans, Eva; Salas-Perdomo, Angelica; Daans, Jasmijn; De Vocht, Nathalie; Shah, Disha; Hoornaert, Chloé; Praet, Jelle; Peerlings, Jurgen; Kara, Firat; Bigot, Christian; Mai, Zhenhua; Hens, Niels; Hendrix, Sven; Verhoye, Marleen; Planas, Anna M; Berneman, Zwi; Van der Linden, Annemie; Ponsaerts, Peter
Detrimental inflammatory responses in the central nervous system are a hallmark of various brain injuries and diseases. With this study we provide evidence that lentiviral vector-mediated expression of the immune-modulating cytokine interleukin 13 (IL-13) induces an alternative activation program in both microglia and macrophages conferring protection against severe oligodendrocyte loss and demyelination in the cuprizone mouse model for multiple sclerosis (MS). First, IL-13 mediated modulation of cuprizone induced lesions was monitored using T2-weighted magnetic resonance imaging and magnetization transfer imaging, and further correlated with quantitative histological analyses for inflammatory cell influx, oligodendrocyte death, and demyelination. Second, following IL-13 immune gene therapy in cuprizone-treated eGFP+ bone marrow chimeric mice, we provide evidence that IL-13 directs the polarization of both brain-resident microglia and infiltrating macrophages towards an alternatively activated phenotype, thereby promoting the conversion of a pro-inflammatory environment toward an anti-inflammatory environment, as further evidenced by gene expression analyses. Finally, we show that IL-13 immune gene therapy is also able to limit lesion severity in a pre-existing inflammatory environment. In conclusion, these results highlight the potential of IL-13 to modulate microglia/macrophage responses and to improve disease outcome in a mouse model for MS.